I'm hoping PAR do not enter into a trading halt just to release the results of a couple of secondary endpoints, it just seems overkill IMO. I've never seen a biopharma company place such a great deal of emphasis into their lower level secondary endpoints than PAR has. Other companies normally just released them to no fanfare at all, but i'm half expecting PAR to go into trading halt over the long weekend in typical PAR style. Anyway I'm hoping to still see some separation between the treatment and placebo groups as this will indicate not only possible durability but also disease-modifying properties.
I'm hoping PAR do not enter into a trading halt just to release...
-
- There are more pages in this discussion • 318 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.015(6.52%) |
Mkt cap ! $85.7M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 24.5¢ | 23.0¢ | $116.0K | 491.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 33682 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |